MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Home・Aktien・ESPERION THERAPEUTICS INC

ESPERION THERAPEUTICS INC

Open

BrancheGesundheitswesen

3.18 11.19

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.8

Max

3.36

Schlüsselkennzahlen
By Trading Economics
Einkommen	28M -13M
Verkäufe	17M 82M
Gewinnspanne	-15.446
Angestellte	304
EBITDA	37M 16M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+138.62% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	6. Nov. 2025

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	239M 534M
Vorheriger Eröffnungskurs	-8.01
Vorheriger Schlusskurs	3.18

Nachrichtenstimmung

By Acuity

58%

42%

314 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

0.85 / 1.05 Unterstützung & Widerstand

ESPERION THERAPEUTICS INC Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Okt. 2025, 23:30 UTC

Heiße Aktien

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2. Okt. 2025, 21:21 UTC

Ergebnisse

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3. Okt. 2025, 00:00 UTC

Akquisitionen, Fusionen, Übernahmen

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2. Okt. 2025, 23:40 UTC

Market Talk

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2. Okt. 2025, 23:39 UTC

Market Talk

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2. Okt. 2025, 23:29 UTC

Akquisitionen, Fusionen, Übernahmen

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2. Okt. 2025, 23:29 UTC

Akquisitionen, Fusionen, Übernahmen

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2. Okt. 2025, 23:29 UTC

Akquisitionen, Fusionen, Übernahmen

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2. Okt. 2025, 23:00 UTC

Market Talk

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2. Okt. 2025, 22:54 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Scales's JV Buyout Lauded by Bull -- Market Talk

2. Okt. 2025, 22:54 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Global Forex and Fixed Income Roundup: Market Talk

2. Okt. 2025, 22:46 UTC

Market Talk

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2. Okt. 2025, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2. Okt. 2025, 21:17 UTC

Akquisitionen, Fusionen, Übernahmen

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2. Okt. 2025, 20:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Energy & Utilities Roundup: Market Talk

2. Okt. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. Okt. 2025, 20:49 UTC

Akquisitionen, Fusionen, Übernahmen

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2. Okt. 2025, 20:00 UTC

Akquisitionen, Fusionen, Übernahmen

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2. Okt. 2025, 19:20 UTC

Market Talk

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2. Okt. 2025, 19:10 UTC

Market Talk

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2. Okt. 2025, 19:04 UTC

Market Talk

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2. Okt. 2025, 18:46 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2. Okt. 2025, 18:46 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2. Okt. 2025, 18:46 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2. Okt. 2025, 18:45 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2. Okt. 2025, 18:45 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2. Okt. 2025, 18:44 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2. Okt. 2025, 18:44 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2. Okt. 2025, 18:44 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2. Okt. 2025, 18:43 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Peer-Vergleich

Kursveränderung

ESPERION THERAPEUTICS INC Prognose

Kursziel

By TipRanks

138.62% Vorteil

12-Monats-Prognose

Durchschnitt 6.92 USD 138.62%

Hoch 16 USD

Tief 1.6 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für ESPERION THERAPEUTICS INC – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für ESPERION THERAPEUTICS INC – Dist abgegeben haben.

Technischer Score

By Trading Central

0.85 / 1.05Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Stimmung

By Acuity

314 / 371 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über ESPERION THERAPEUTICS INC

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.